CXCR3 and neoplasm: To further address the potential for on-target, off-tumor effects of 4G5 FAP-CAR T cells, we treated 4662 PDAC tumor-bearing syngeneic C57BL/6 mice with two doses of MigR control or FAP-CAR T cells and collected multiple organs from one cohort at 1 week after the first dose and from a second cohort at 1 week after the second dose.